Mandate

Vinge acted as local counsel in relation to the sale of Phadia, the biotechnology company, for SEK 22 billion

May 20, 2011

Cinven has entered into an agreement with Thermo Fisher Scientific to sell the Uppsala based biotechnology company, Phadia Group, for SEK 22 billion. Phardia is a spin-off from the former Pharmacia and enjoys a leading position within allergy testing.

Vinge acted as local counsel advising on Swedish legal issues for Cinven/Freshfields. Vinge's team consisted of partner Christina Kokko and associates Joacim Rydergård, Jonas Bergström, Alex Miller and Albert Wållgren.

Related

Vinge advises Symrise on its public offer for Probi

Symrise AG has announced a public cash offer to the shareholders of Probi AB (publ) (“Probi”). The offer values Probi at approximately SEK 3,988 million. The shares in Probi are traded on Nasdaq Stockholm, Mid Cap.
November 20, 2024

Vinge advises Oxx in conjunction with an investment in Kodiak Hub

Kodiak Hub, a Swedish software as a service (SaaS) company, which offers its customers an AI-based software platform, has performed a capital procurement of EUR 6 million. The venture capital fund Oxx, which invests in SaaS companies, is the largest investor.
November 20, 2024

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited

Semmco Group is a UK market-leading manufacturer and supplier of maintenance platforms and stairs for aircraft and trains.
November 19, 2024